To further assess the clinical relevance of our findings, weinvestigated the potential of combining SMARCA2/4 PROTAC degrader treatment withchemotherapy (cisplatin and etoposide), the standard of care for SCLCpatients.30,31In vitro synergy was assessed between chemotherapy (cisplatinor etoposide) and AU-24118 in multiple SCLC-P cell lines, but results showed nosignificant synergy with either AU-15330 and cisplatin or AU-15330 and etoposide(FiguresS4A–S4C). The gene discussed is SMARCA2; the disease is small cell lung carcinoma.